Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F et al (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s disease: safety and efficacy results from a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurol Ther 12(6):1937–1958

Article  PubMed  PubMed Central  Google Scholar 

Alfonso D, Cabrera LY, Sidiropoulos C, Wang F, Sarva H (2022) How Parkinson’s patients in the USA perceive deep brain stimulation in the 21st century: Results of a nationwide survey. J Clin Neurosci 95:20–26

Article  CAS  PubMed  Google Scholar 

Ansari J (2010) Drug interaction and pharmacist. J Young Pharm 2(3):326–331

Article  PubMed  PubMed Central  Google Scholar 

Antonini A (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease. J Mov Disord 2(1):4–9

Article  PubMed  PubMed Central  Google Scholar 

Antonini A, Odin P (2009) Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 4):S97-100

Article  PubMed  Google Scholar 

Antonini A, Tolosa E (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurother 9(6):859–867

Article  CAS  PubMed  Google Scholar 

Antonini A, Odin P, Schmidt P, Cubillos F, Standaert DG, Henriksen T et al (2021) Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson’s disease patients inadequately controlled on oral medications. Parkinsonism Relat Disord 92:59–66

Article  CAS  PubMed  Google Scholar 

Aradi SD, Hauser RA (2020) Medical Management and Prevention of Motor Complications in Parkinson’s Disease. Neurotherapeutics 17(4):1339–1365

Article  PubMed  PubMed Central  Google Scholar 

Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6):548–560

Article  PubMed  Google Scholar 

Auffret M, Weiss D, Stocchi F, Vérin M, Jost WH (2023) Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty. J Neural Transm (vienna) 130(11):1411–1432

Article  PubMed  Google Scholar 

Badihian N, Jackson LM, Klassen BT, Hassan A, Low PA, Singer W et al (2022) The effects of deep brain stimulation in patients with multiple system atrophy. J Parkinsons Dis 12(8):2595–2600

Article  PubMed  PubMed Central  Google Scholar 

Basiago A, Binder DK (2016) Effects of deep brain stimulation on autonomic function. Brain Sci 6(3):33

Article  PubMed  PubMed Central  Google Scholar 

Bhidayasiri R, Jitkritsadakul O, Boonrod N, Rerknimitr R (2014) Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy. Clin Neurol Neurosurg 116:1–3

Article  PubMed  Google Scholar 

Bhidayasiri R, Ray Chaudhuri K, LeWitt P, Martin A, Boonpang K, van Laar T (2015) Effective delivery of apomorphine in the management of Parkinson disease. Clin Neuropharmacol 38:89–103

Article  CAS  PubMed  Google Scholar 

Bhidayasiri R, Boonpang K, Jitkritsadakul O, Calne SM, Henriksen T, Trump S et al (2016a) Understanding the role of the Parkinson’s disease nurse specialist in the delivery of apomorphine therpy. Parkinsonism Relat Disord 33(Suppl 1):S49-s55

Article  PubMed  Google Scholar 

Bhidayasiri R, Sringean J, Anan C, Boonpang K, Thanawattano C, Ray CK (2016b) Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson’s disease using wearable sensors. Parkinsonism Relat Disord 33(Suppl 1):S36–S41

Article  PubMed  Google Scholar 

Bhidayasiri R, Phokaewvarangkul O, Sakdisornchai K, Boonpang K, Chaudhuri KR, Parsons J et al (2020) Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson’s disease management in developing countries. Expert Rev Neurother 20(6):523–537

Article  CAS  PubMed  Google Scholar 

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211

Article  PubMed  Google Scholar 

Burack M, Aldred J, Zadikoff C, Vanagunas A, Klos K, Bilir B et al (2018) Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners. Mov Disord Clin Pract 5(4):383–393

Article  PubMed  PubMed Central  Google Scholar 

Cabrera LY, Young Han C, Ostendorf T, Jimenez-Shahed J, Sarva H (2021) Neurologists’ attitudes toward use and timing of deep brain stimulation. Neurol Clin Pract 11(6):506–516

Article  PubMed  PubMed Central  Google Scholar 

Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol 9(11):1106–1117

Article  CAS  PubMed  Google Scholar 

Cochen De Cock V, Dodet P, Leu-Semenescu S, Aerts C, Abril B, Castelnovo G et al (2023) Night-Time Apomorphine Infusion: Who Are the Best Candidates? Mov Disord Clin Pract. 10(8):1192–1197

Article  PubMed  PubMed Central  Google Scholar 

Collomb-Clerc A, Welter ML (2015) Effects of deep brain stimulation on balance and gait in patients with Parkinson’s disease: a systematic neurophysiological review. Neurophysiol Clin 45(4–5):371–388

Article  CAS  PubMed  Google Scholar 

Constantin VA, Szasz JA, Orban-Kis K, Rosca EC, Popovici M, Cornea A et al (2020) Levodopa-Carbidopa intestinal gel infusion therapy discontinuation: a ten-year retrospective analysis of 204 treated patients. Neuropsychiatr Dis Treat 16:1835–1844

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng H, Wang P, Jankovic J (2018) The genetics of Parkinson disease. Ageing Res Rev 42:72–85

Article  CAS  PubMed  Google Scholar 

Dietrichs E, Odin P (2017) Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol Scand 136(5):378–385

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drapier S, Gillioz AS, Leray E, Peron J, Rouaud T, Marchand A et al (2012) Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord 18(1):40–44

Article  PubMed  Google Scholar 

Du J, Liu X, Zhou X, Wang H, Zhou W, Jiang J et al (2020) Parkinson’s disease-related risk of suicide and effect of deep brain stimulation: meta-analysis. Parkinsons Dis 2020:8091963

PubMed  PubMed Central  Google Scholar 

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K et al (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33(8):1248–1266

Article  CAS  PubMed  Google Scholar 

Freitas ME, Hess CW, Fox SH (2017) Motor complications of dopaminergic medications in Parkinson’s disease. Semin Neurol 37(2):147–157

Article  PubMed  PubMed Central  Google Scholar 

Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M et al (2024) Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: sonsiderations for initiation and maintenance. Clin Park Relat Disord 10:100239

PubMed  PubMed Central  Google Scholar 

Georgiev D, Delalic S, Zupancic Kriznar N, Socher A, Gurevich T, Trost M (2022) Switching and combining device-aided therapies in advanced parkinson’s disease: a double centre retrospective study. Brain Sci 12(3):343

Article  PubMed  PubMed Central  Google Scholar 

Hariz M, Blomstedt P (2022) Deep brain stimulation for Parkinson’s disease. J Intern Med 292(5):764–778

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henriksen T, Staines H (2021) Continuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation. J Pers Med. 11(6):525

Article  PubMed  PubMed Central  Google Scholar 

Henriksen T, Dalhoff KP, Hansen HE, Brenneche AW, Lonberg US, Danielsen EH (2020) Access and use of device-aided therapies for parkinson’s disease in denmark. Mov Disord Clin Pract 7(6):656–663

Article  PubMed  PubMed Central  Google Scholar 

Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ (1992) The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 55(11):1009–1013

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence. Parkinson’s disease in adults, 19 July 2017. www.nice.org.uk/guidance/ng71.

Jing XZ, Yuan XZ, Luo X, Zhang SY, Wang XP (2023) An update on nondopaminergic treatments for motor and non-motor symptoms of Parkinson’s disease. Curr Neuropharmacol 21(8):1806–1826